



HEALTHCARE  
LEADERSHIP  
COUNCIL

March 2, 2017

The Honorable Michael C. Burgess, M.D.  
Chairman  
U.S. House Energy and Commerce  
Subcommittee on Health  
2125 Rayburn House Office Building  
Washington, D.C. 20515

The Honorable Gene Green  
Ranking Member  
U.S. House Energy and Commerce  
Subcommittee on Health  
2322A Rayburn House Office Building  
Washington, D.C. 20515

Dear Chairman Burgess and Ranking Member Green:

The Healthcare Leadership Council (HLC) appreciates the opportunity to submit a statement for the record regarding the Energy and Commerce Subcommittee on Health hearing on, “Examining FDA’s Generic Drug and Biosimilar User Fee Programs.” HLC strongly supports private sector competition as a tool to ensure high-value healthcare and believes in a robust, transparent Food and Drug Administration to improve the lives of consumers.

HLC is a coalition of chief executives from all disciplines within American healthcare. It is the exclusive forum for the nation’s healthcare leaders to jointly develop policies, plans, and programs to achieve their vision of a 21st century health system that makes affordable, high-quality care accessible to all Americans. Members of HLC—hospitals, academic health centers, health plans, pharmaceutical companies, medical device manufacturers, biotech firms, health product distributors, pharmacies, post-acute care providers, and information technology companies—believe that the issue of healthcare costs should be addressed through competition in a transparent, consumer-oriented healthcare marketplace.

HLC believes that generic drugs are one of many treatment options that consumers and their doctors rely upon among a full range of high-value treatment options. We support the approach of the “Lower Drug Costs through Competition Act” (H.R. 749) to relieve the backlog of generic drug approvals and encourage the committee to remain open to also consider strategies that work in tandem with existing private sector initiatives to drive higher-value care.

As leaders from the full spectrum of American healthcare, we have long maintained that affordability and accessibility must be health system priorities. We also believe that affordability and innovation can, and must, co-exist. We applaud your leadership in reviewing important legislation to further these goals. Please feel free to contact HLC’s SVP for Policy, Tina Grande ([tgrande@hlc.org](mailto:tgrande@hlc.org) or 202-449-3433), with any questions.

Sincerely,



Mary R. Grealy  
President